Three cases of severe ulcerative esophagitis induced by SUTENT®.
BACKGROUND
The development of SUTENT® revolutionized the care of metastatic renal carcinoma and of non-operable GIST. The tolerance is quite good with mostly mild side effects grade 1 or 2.


METHODS
We report the case of three severe esophagitis stage 4 responsible for digestive bleeding. Two patients were taking anti-coagulant that could worsen the bleeding, but none were taking either antiplatelet or non-steroidal anti-inflammatory or corticosteroid that could favour erosion or ulceration of the digestive mucosa. It seems that SUTENT® is responsible for the digestive bleeding.


CONCLUSIONS
Cases of esophagitis induced by SUTENT® have already been reported but are rare and of mild severity. Our three cases of esophagitis are severe with SUTENT® treatment as only risk factor and worsened by anti-coagulant treatment for two patients. It might be of interest preventively to treat these patients with inhibitors of proton pump.
Jeanniard-Malet
Odile
O
Department of Oncological Medico-Surgical Explorations, Institut Paoli-Calmettes, Marseille, France. odile.malet@yahoo.fr
Gravis
Gwenaëlle
G
Caillol
Fabrice
F
Pesenti
Christian
C
Bories
Erwan
E
Giovannini
Marc
M
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D004941:Esophagitis / Q000139:chemically induced*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib; D014456:Ulcer / Q000139:chemically induced
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib